Land: Irland
Språk: engelska
Källa: HPRA (Health Products Regulatory Authority)
PARACETAMOL CODEINE PHOSPHATE HEMIHYDRATE CAFFEINE
GlaxoSmithKline Consumer Healthcare (Ireland) Limited
500/8/30 Milligram
Tablets
1993-10-29
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Solpadeine Tablets Paracetamol 500mg, Codeine Phosphate Hemihydrate 8mg, Caffeine 30mg 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains paracetamol 500 mg, codeine phosphate hemihydrate 8 mg and caffeine 30.0 mg. Excipients: contains Carmoisine (E122) For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Tablet White capsule shaped tablets, printed ‘Solpadeine’ in red on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the management of symptoms of headache, including migraine, toothache, backache, common cold, influenza, menstrual pain, musculoskeletal pain. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For oral administration only. Adults (including the elderly) and children aged 12 years and over: The usual dose is two tablets three to four times in a 24 hour period as required. Children under 12: Not recommended in children under 12 years of age. The dose should not be repeated more frequently than every 4 hours. A maximum of 8 tablets in 24 hours should not be exceeded. Do not exceed the stated dose or take for more than 3 days without consulting a doctor. Should not be used with other paracetamol or codeine containing products. Renal Impairment Patients who have been diagnosed with kidney impairment must seek medical advice before taking this medication. Hepatic Impairment Patients who have been diagnosed with liver impairment must seek medical advice before taking this medication 4.3 CONTRAINDICATIONS Hypersensitivity to paracetamol, codeine, caffeine or any of the other constituents. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 21/04/2011_ _CRN 2098789_ _page number: 1_ Acute Läs hela dokumentet